drugset / Trial / NCT06402123
A Phase 2b Study of Zagociguat in Patients With MELAS
RandomizedCrossoverQuadruple-blindTreatment
Summary
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Timeline
- Start
- 2024-09-10
- Primary completion
- 2026-06-29
- Completion
- 2026-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zagociguat | Small molecule | 15 mg | Oral |
| Subject | zagociguat | Small molecule | 30 mg | Oral |